MX2016011401A - Composiciones farmaceuticas que comprenden levocetirizina. - Google Patents

Composiciones farmaceuticas que comprenden levocetirizina.

Info

Publication number
MX2016011401A
MX2016011401A MX2016011401A MX2016011401A MX2016011401A MX 2016011401 A MX2016011401 A MX 2016011401A MX 2016011401 A MX2016011401 A MX 2016011401A MX 2016011401 A MX2016011401 A MX 2016011401A MX 2016011401 A MX2016011401 A MX 2016011401A
Authority
MX
Mexico
Prior art keywords
levocetirizine
pharmaceutical compositions
relates
pharmaceutical composition
present
Prior art date
Application number
MX2016011401A
Other languages
English (en)
Other versions
MX371443B (es
Inventor
Fanara Domenico
Goole Jonathan
Deleers Michel
Original Assignee
Ucb Farchim Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Farchim Sa filed Critical Ucb Farchim Sa
Publication of MX2016011401A publication Critical patent/MX2016011401A/es
Publication of MX371443B publication Critical patent/MX371443B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende levocetirizina. La invención se refiere específicamente a una formulación de jarabe seco.
MX2016011401A 2014-03-27 2015-03-26 Composiciones farmaceuticas que comprenden levocetirizina. MX371443B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14162001 2014-03-27
EP14161997 2014-03-27
PCT/EP2015/056593 WO2015144830A1 (en) 2014-03-27 2015-03-26 Pharmaceutical compositions comprising levocetirizine

Publications (2)

Publication Number Publication Date
MX2016011401A true MX2016011401A (es) 2017-04-06
MX371443B MX371443B (es) 2020-01-30

Family

ID=52774233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011401A MX371443B (es) 2014-03-27 2015-03-26 Composiciones farmaceuticas que comprenden levocetirizina.

Country Status (15)

Country Link
US (3) US20170105988A1 (es)
EP (1) EP3122330B1 (es)
JP (2) JP6506301B2 (es)
KR (1) KR102445606B1 (es)
CN (2) CN106102715A (es)
BR (1) BR112016022126B1 (es)
CA (1) CA2940920C (es)
DK (1) DK3122330T3 (es)
EA (1) EA036278B1 (es)
ES (1) ES2691920T3 (es)
HU (1) HUE039791T2 (es)
MX (1) MX371443B (es)
PL (1) PL3122330T3 (es)
PT (1) PT3122330T (es)
WO (1) WO2015144830A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102110304B1 (ko) * 2017-06-30 2020-05-14 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법
JP6986244B2 (ja) * 2017-09-27 2021-12-22 高田製薬株式会社 レボセチリジン固形製剤
MX2023003432A (es) * 2020-09-29 2023-08-04 Millicent Pharma Ltd Formulaciones orodispersables.
US20230414597A1 (en) 2020-11-18 2023-12-28 BioPharma Synergies, S. L. Orodispersible powder composition comprising an antihistamine compound

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
EP1467715B1 (en) * 2002-01-15 2010-11-03 Ucb Farchim S.A. Formulations for oral administration of active compounds
US20060083786A1 (en) * 2004-07-29 2006-04-20 Glenmark Pharmaceuticals Limited Taste masking pharmaceutical composition containing levocetirizine
US8962022B2 (en) * 2007-03-27 2015-02-24 Aptalis Pharmatech, Inc. Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family
WO2008149894A1 (ja) * 2007-06-06 2008-12-11 Asahi Kasei Chemicals Corporation セルロース系微小核粒子及びその製造方法
JP5291324B2 (ja) * 2007-11-01 2013-09-18 沢井製薬株式会社 口腔内崩壊錠
WO2011110939A2 (en) * 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
JP2013159587A (ja) * 2012-02-07 2013-08-19 Riken Vitamin Co Ltd レイヤリング用核粒子の製造方法
JP6176840B2 (ja) * 2012-06-29 2017-08-09 高田製薬株式会社 フェキソフェナジン顆粒製剤及びその製造方法
CN102860986A (zh) * 2012-09-28 2013-01-09 天津市聚星康华医药科技有限公司 一种稳定的掩味的左西替利嗪药物组合物及其制备方法

Also Published As

Publication number Publication date
EA201691924A1 (ru) 2017-02-28
JP6820116B2 (ja) 2021-01-27
HUE039791T2 (hu) 2019-02-28
PL3122330T3 (pl) 2019-01-31
CN106102715A (zh) 2016-11-09
US20210251984A1 (en) 2021-08-19
PT3122330T (pt) 2018-11-13
MX371443B (es) 2020-01-30
BR112016022126A2 (pt) 2021-08-03
US20170105988A1 (en) 2017-04-20
KR102445606B1 (ko) 2022-09-20
WO2015144830A1 (en) 2015-10-01
US20200297718A1 (en) 2020-09-24
EP3122330B1 (en) 2018-07-25
EP3122330A1 (en) 2017-02-01
JP6506301B2 (ja) 2019-04-24
JP2017508761A (ja) 2017-03-30
JP2018184436A (ja) 2018-11-22
EA036278B1 (ru) 2020-10-21
ES2691920T3 (es) 2018-11-29
CN111632023A (zh) 2020-09-08
KR20160137521A (ko) 2016-11-30
DK3122330T3 (en) 2018-10-22
BR112016022126B1 (pt) 2023-05-02
CA2940920C (en) 2023-08-29
CA2940920A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
IL271657A (en) medical preparation
HK1225655A1 (zh) 包含azd9291的藥用組合物
EP3129028A4 (en) Pharmaceutical compositions
GB201419257D0 (en) Pharmaceutical compositions
EP3160491A4 (en) Pharmaceutical compositions
GB201608323D0 (en) Pharmaceutical compositions
GB201705303D0 (en) Pharmaceutical compositions
SG11202001179YA (en) Pharmaceutical compositions
GB201705305D0 (en) Pharmaceutical compositions
MX371443B (es) Composiciones farmaceuticas que comprenden levocetirizina.
GB201705306D0 (en) Pharmaceutical compositions
GB201705304D0 (en) Pharmaceutical compositions
EP3191093A4 (en) Pharmaceutical compositions
IL263999A (en) Pharmaceutical compositions
PT3200772T (pt) Composições farmacêuticas compreendendo alpelisib
IL272044A (en) Pharmacy preparations
ZA201705782B (en) Pharmaceutical compositions
IL272428A (en) pharmaceutical preparations
ZA202000014B (en) Pharmaceutical compositions
GB201715881D0 (en) New pharmaceutical compositions
GB201715404D0 (en) Pharmaceutical compositions
ZA201705783B (en) Pharmaceutical compositions
GB201710114D0 (en) Pharmaceutical compositions
GB201706816D0 (en) Pharmaceutical compositions
GB201705301D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FG Grant or registration